- Home
- SATX vs ADCT Comparison
SATX vs ADCT Comparison
Compare SATX & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SATX
- ADCT
- Stock Information
- Founded
- SATX 2012
- ADCT 2011
- Country
- SATX Israel
- ADCT Switzerland
- Employees
- SATX N/A
- ADCT N/A
- Industry
- SATX Radio And Television Broadcasting And Communications Equipment
- ADCT Biotechnology: Pharmaceutical Preparations
- Sector
- SATX Technology
- ADCT Health Care
- Exchange
- SATX Nasdaq
- ADCT Nasdaq
- Market Cap
- SATX 251.3M
- ADCT 241.0M
- IPO Year
- SATX N/A
- ADCT 2020
- Fundamental
- Price
- SATX $2.90
- ADCT $2.78
- Analyst Decision
- SATX Strong Buy
- ADCT Strong Buy
- Analyst Count
- SATX 2
- ADCT 6
- Target Price
- SATX $2.25
- ADCT $7.80
- AVG Volume (30 Days)
- SATX 298.8K
- ADCT 937.9K
- Earning Date
- SATX 05-22-2025
- ADCT 08-05-2025
- Dividend Yield
- SATX N/A
- ADCT N/A
- EPS Growth
- SATX N/A
- ADCT N/A
- EPS
- SATX N/A
- ADCT N/A
- Revenue
- SATX $23,654,000.00
- ADCT $75,817,000.00
- Revenue This Year
- SATX $50.67
- ADCT $10.65
- Revenue Next Year
- SATX $1.64
- ADCT $15.05
- P/E Ratio
- SATX N/A
- ADCT N/A
- Revenue Growth
- SATX 130.79
- ADCT 10.49
- 52 Week Low
- SATX $0.58
- ADCT $1.05
- 52 Week High
- SATX $2.97
- ADCT $4.13
- Technical
- Relative Strength Index (RSI)
- SATX 79.84
- ADCT 47.62
- Support Level
- SATX $2.88
- ADCT $3.21
- Resistance Level
- SATX $2.90
- ADCT $3.97
- Average True Range (ATR)
- SATX 0.02
- ADCT 0.38
- MACD
- SATX -0.03
- ADCT -0.12
- Stochastic Oscillator
- SATX 91.67
- ADCT 3.43
About SATX SatixFy Communications Ltd.
SatixFy Communications Ltd is engaged in developing end-to-end next-generation satellite communication systems. This includes satellite payloads, user terminals, and modems, which are built on powerful in-house designed chipsets. Their products feature modems equipped with Software Defined Radio and Fully Electronically Steered Multi Beam Antennas that support the entire DVB-RCS2 / DVB-S2X industry standards as well as a complete SDR for any other waveform. The company has a geographical presence in the U.S. & Canada, the UK, and Other countries, with the majority of its revenue generated from the U.S. and Canada.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).